OM
NERV icon

Opaleye Management’s Minerva Neurosciences NERV Stock Holding History

Opaleye Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-95,925
Closed -$2.44M – 62
2020
Q3 		$2.44M Buy
+95,925
New +$2.59M 0.48% 43
2020
Q2 		– Sell
-56,263
Closed -$2.71M – 50
2020
Q1 		$2.71M Buy
+56,263
New +$3.39M 0.72% 32

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opaleye Management's NERV Position: Q4 2020 in Review

Opaleye Management sold out of Minerva Neurosciences (NERV) in Q4 2020, closing a stake of 95,925 shares — an estimated $2.44M sold.

Opaleye Management first reported a position in NERV in Q1 2020 and held it in 2 quarters. The position peaked at $2.71M in Q1 2020. 76 funds tracked by Wall St. Rank hold NERV as of Q4 2020.

  • Opaleye Management reported no remaining Minerva Neurosciences position as of Q4 2020 after selling out during the quarter.
  • Opaleye Management sold 95,925 Minerva Neurosciences shares in Q4 2020, an estimated $2.44M.
  • Opaleye Management first reported a position in Minerva Neurosciences in Q1 2020 and held it in 2 quarters.
  • Opaleye Management's Minerva Neurosciences position peaked at $2.71M in Q1 2020.
  • 76 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2020.

Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.